Efficacy and Safety of Guselkumab in Participants with Active Psoriatic Arthritis After Inadequate Response to One Prior Tumor Necrosis Factor Inhibitor: Week‐24 Results of the Phase 3, Randomized, Placebo‐Controlled SOLSTICE Study

Comparable efficacy was observed with both guselkumab regimens in TNFi-IR participants with active PsA; safety findings were consistent with the known profile of guselkumab in patients with psoriatic disease.